Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$129.0M
23M shares
52-week range
$3.71 – $7.75
58% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
www.coyatherapeutics.comNo one on the platform currently holds COYA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 103,964 | $409.6K |
No one on the platform has traded COYA yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$GANX In my mind, it's not if, but who, when and how much they ultimately pay for Gain. Only way out for pharma is to acquire their way out. Not speculation, but a simple fact. Both it and $COYA will have new names on the door soon enough.
View on StockTwits ↗$COYA Great evidence that Coya-302 is working. While this is a blind placebo controlled study you cant fool ALS for long as it is a devastating disease. No doctor would make these types of comments unless the patient has been on the drug for a while and has shown true benefits. Just like all the previous studies it works and also works for FTD. Someone needs to buy them before that study launches.
View on StockTwits ↗$ABCL $GANX $COYA Nice day for all three and let us not forget $SLS. Bio is seeing big inflows and smaller names are all acquisition targets.
View on StockTwits ↗$COYA $GANX Stay the course and remember... Coya just recieved fast track designation. One would think Gain may soon receive the same now that the IND was accepted. Both companies likely have new names on the door by year end in my mind. Billionaire investor David Einhorn owns large positions in both, his two smallest cap investments. DYDD
View on StockTwits ↗$COYA Got in early here at 4.60 after all the cross posts from Ganx - very happy! amazing company, amazing team, amazing returns
View on StockTwits ↗$COYA If you're new: https://medium.com/@killian.sheehan/the-100-million-anomaly-why-david-einhorn-chose-a-nobel-prize-biotech-over-the-ai-bubble-a9f4d1ff1740
View on StockTwits ↗$COYA Dr. Merit Cudkowicz is Executive Director of the MGH Brigham Neuroscience Institute and Director of the Sean M. Healey & AMG Center for ALS at Mass General and listed as an expert clinical advisor to Coya, providing ALS-development expertise for COYA 302. Coya has an active ALSTARS Phase 2 COYA 302 ALS trial site at MGH. Mass General has an official donation page in honor of Chris Johnson supporting the Sean M. Healey & AMG Center for ALS—the MGH ALS center led by Dr. Merit Cudkowicz. Public reporting indicates that Dr. Merit Cudkowicz is working with Chris Johnson on his ALS care and clinical-trial treatment Very interesting connections to Chris Johnson, MGH and Coya. Sounds like he is getting top care and glad to see our own Dr. Cudkowicz involved.
View on StockTwits ↗$COYA Dr Merit Cudkowicz who was on the Good Morning America segment was brought on by COYA July 23rd 2023 and believes in the Tregs and putting out fire abatacept therapy. The above is accurate...I believe its COYA treating Chris Johnson.
View on StockTwits ↗$COYA Dr Merit Cudkowicz treating Superstar NFL Player Chris Johnson was brought in by COYA ....I am fairly certain of that in my opinion. The Interview stated at Mass General helping Chris with his inflammation. It sounds to me Tregs are getting enhanced and the bad guys being supressed.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.